Antifibrotic effect of curcumin in TGF-β1-induced myofibroblasts from human oral mucosa

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 289-294

  Zhang, Shan Shan ^a   Gong, Zhao Jian ^a   Li, Wen Hui ^a   Wang, Xiao ^a   Ling, Tian You ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Curcumin; Myofibroblast; Oral submucous fibrosis

Indexed keywords

BAX PROTEIN, HUMAN; COLLAGEN TYPE 1; CURCUMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BAX; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FLOW CYTOMETRY; HUMAN; INFANT; METABOLISM; MOUTH DISEASE; MOUTH MUCOSA; MYOFIBROBLAST; PATHOLOGY; PRESCHOOL CHILD; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHILD, PRESCHOOL; COLLAGEN TYPE I; CURCUMIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MOUTH MUCOSA; MYOFIBROBLASTS; ORAL SUBMUCOUS FIBROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84864869467     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.289     Document Type: Article

References (36)

1. Angadi PV, Kale AD, Hallikerimath S (2011). Evaluation of myofibroblasts in oral submucous fibrosis: correlation with disease severity. J Oral Pathol Med, 40, 208-13.
2. Atsumi T, Tonosaki K, Fujisawa S (2006). Induction of early apoptosis and ROS-generation activity in human gingival fibroblasts (HGF) and human submandibular gland carcinoma (HSG) cells treated with curcumin. Arch Oral Biol, 51, 913-21.
3. Boucher BJ, Mannan N (2002). Metabolic effects of the consumption of Areca catechu. Addict Biol, 7, 103-10.
4. Bruck R, Ashkenazi M, Weiss S, et al (2007). Prevention of liver cirrhosis in rats by curcumin. Liver Int, 27, 373-83.
5. Chen A, Xu J (2005). Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol, 288, G447-56.
6. Chen A, Xu J, Johnson AC (2006). Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene, 25, 278-87.
7. Choudhuri T, Pal S, Das T, Sa G (2005). Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem, 280, 20059-68.
8. Divya CS, Pillai MR (2006). Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog, 45, 320-32.
9. Elledge SJ (1996). Cell cycle checkpoints: preventing an identity crisis. Science, 274, 1664-72.
10. Fedorowicz Z, Chan Shih-Yen E, Dorri M, et al (2008). Interventions for the management of oral submucous fibrosis. Cochrane Database Syst Rev, 8, CD007156.
11. Gabbiani G (2003). The myofibroblast in wound healing and fibrocontractive diseases. J Pathol, 200, 500-3.
12. Goel A, Jhurani S, Aggarwal BB (2008). Multi-targeted therapy by curcumin: how spicy is it?. Mol Nutr Food Res, 52, 1010-30.
13. Hinz B, Phan SH, Thannickal VJ, et al (2007). The myofibroblast: one function, multiple origins. Am J Pathol, 170, 1807-16.
14. International Agency for Research on Cancer (2005). WHO classification of tumors: pathology and genetics of head and neck tumors. IARC Press, Lyon.
15. Jackson JK, Higo T, Hunter WL, Burt HM (2006). The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res, 55, 168-75.
16. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK (1996). Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer, 26, 111-20.
17. Jiang X, Hu J (2009). Drug treatment of oral submucous fibrosis: a review of the literature. J Oral Maxillofac Surg, 67, 1510-5.
18. Kerr AR, Warnakulasuriya S, Mighell AJ, et al (2011). A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. Oral Dis, 1, 42-57.
19. Lin YL, Lin CY, Chi CW, Huang YT (2009). Study on antifibrotic effects of curcumin in rat hepatic stellate cells. Phytother Res, 23, 927-32.
20. Liu HS, Ke CS, Cheng HC, Huang CY, Su CL (2011). Curcumininduced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of Aurora A. Mol Pharmacol, 80, 638-46.
21. Miyashita T, Krajewski S, Krajewska M, et al (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799-805.
22. Miyashita T, Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293-9.
23. Montopoli M, Ragazzi E, Froldi G, Caparrotta L (2009). Cellcycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. Cell Prolif, 42, 195-206.
24. Osawa T (2007). Nephroprotective and hepatoprotective effects of curcuminoids. Adv Exp Med Biol, 595, 407-23.
25. Powell DW, Mifflin RC, Valentich JD, et al (1999). Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol, 277, C1-9.
26. Puliyappadamba VT, Cheriyan VT, Thulasidasan AK, et al (2010). Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its downregulation by curcumin is independent. Mol Cancer, 9, 220.
27. Rajalalitha P, Vali S (2005). Molecular pathogenesis of oral submucous fibrosis--a collagen metabolic disorder. J Oral Pathol Med, 34, 321-8.
28. Rivera-Espinoza Y, Muriel P (2009). Pharmacological actions of curcumin in liver diseases or damage. Liver Int, 29, 1457-66.
29. Singh M, Chaudhary AK, Pandya S, et al (2010). Morphometric analysis in potentially malignant head and neck lesions: oral submucous fibrosis. Asian Pac J Cancer Prev, 11, 257-60.
30. Smith MR, Gangireddy SR, Narala VR, et al (2010). Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol, 298, L616-25.
31. Strimpakos AS, Sharma RA (2008). Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal, 10, 511-45.
32. Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S (2006). Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol, 42, 561-8.
33. Utsunomiya H, Tilakaratne WM, Oshiro K, et al (2005). Extracellular matrix remodeling in oral submucous fibrosis: its stage-specific modes revealed by immunohistochemistry and in situ hybridization. J Oral Pathol Med, 34, 498-507.
34. Venkatesan N, Punithavathi D, Babu M (2007). Protection from acute and chronic lung diseases by curcumin. Adv Exp Med Biol, 595, 379-405.
35. Watsky MA, Weber KT, Sun Y, Postlethwaite A (2010). New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies. Int Rev Cell Mol Biol, 282, 165-92.
36. Wu SH, Hang LW, Yang JS, et al (2010). Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res, 30, 2125-33.